<p>股息增长股票可以是任何投资组合的理想长期选择。这是因为它们不仅提供良好的分红，而且随着时间的推移可能会升值，从而帮助抵消通货膨胀的负面影响。在最佳情况下，经过通货膨胀调整后的收入最终会随着时间的推移而增加。</p>
<p>目前有许多值得考虑的优质股息股票，因为它们的估值适中。特别是有三只股票的收益率较高，分红增长，并且看起来便宜。它们是 <strong>埃克森美孚</strong>(XOM 0.83%)、<strong>威瑞森</strong>(VZ -0.59%) 和 <strong>艾伯维</strong>(ABBV 0.12%)。</p>
<p>以下是您可能想要考虑今天购买这三只便宜的股息增长股票的原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjAwODYvYS1jb3VwbGUtc2hha2luZy1oYW5kcy13aXRoLWFuLWFkdmlzb3IuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjAwODYvYS1jb3VwbGUtc2hha2luZy1oYW5kcy13aXRoLWFuLWFkdmlzb3IuanBnJnc9NzAw"/></p>
<p>图片来源：Getty Images。</p>
<h2>1. 埃克森美孚</h2>
<p>石油和天然气巨头埃克森美孚已经连续 42 年增加其年度股息。这在考虑到能源市场固有的波动性以及这对石油和天然气生产商的收入和利润的影响时，实在令人印象深刻。</p>
<p>目前，该股票的收益率为 3.76%，高于 <strong>标准普尔 500</strong> 的平均收益率 1.3%，也高于其三年平均收益率 3.4%。这也是一只相对便宜的股票，因为埃克森美孚的市盈率不到 14 倍。</p>
<p>多年来，由于收购，该业务规模不断扩大，这使其变得更加高效和盈利。去年，它完成了对先锋自然资源公司的收购，这一举措使其在二叠纪盆地的生产能力增加了一倍多。</p>
<p>无论是从股息收入还是长期稳定性来看，埃克森美孚都是一只值得购买和持有的优秀股票。</p>
<h2>2. 威瑞森</h2>
<p>该名单中收益率最高的股票是威瑞森。它的收益率为 6.2%，略高于过去五年的平均 5.8%。这一高收益率的一个主要原因是该股票表现不佳，在过去五年中下跌超过 22%。高利率、缺乏增长以及资本密集型业务使得该股票对投资者看起来相当不具吸引力。</p>
<p>但如果您的优先考虑是稳定的股息，那么考虑到其适中的估值，这可以是一只很好的购买股票。该电信股票的市盈率不到 11 倍。尽管其增长前景可能并不理想，但也并非糟糕。公司仍预计今年核心无线服务业务的增长在 2% 到 2.8% 之间。预计自由现金流至少为 175 亿美元，远高于其每年支付的 110 亿美元股息，因此其分红仍然看起来安全。</p>
<p>威瑞森已经连续 18 年增加其股息，对于收入投资者来说，这可以是一只优秀的持有股票，因为其适中的估值为投资者提供了良好的安全边际。</p>
<h2>3. 艾伯维</h2>
<p>该名单的最后一项是医疗公司艾伯维。追溯到它作为 <strong>雅培</strong> 的一部分（2013 年分拆），该股票在技术上被归类为股息之王，其年度增长的连续记录超过 50 年。艾伯维可以为投资者提供两全其美的选择，因为它是一家不断增长的制药公司，并且提供吸引人的股息，目前的收益率为 3.5%。</p>
<p>该股票看起来较贵，市盈率约为 80 倍，但其数字受到收购相关费用的影响，在第四季度的业绩中拖累了其利润，导致其净利润为负。这仍然影响着其市盈率。但根据分析师的预期，该制药公司的股票仅以 15 倍的估计未来利润进行交易。</p>
<p>艾伯维是一家顶尖的医疗公司，拥有广泛的产品组合，涵盖免疫学、肿瘤学、神经科学，甚至美容（它拥有 Botox）。对于增长和股息投资者来说，这可以是一只值得现在购买的优质股票。</p>

埃克森美孚

艾伯维

威瑞森

<p>本文强调了三只值得考虑的股息增长股票：埃克森美孚、威瑞森通讯和艾伯维。埃克森美孚的股息收益率为 3.76%，并且有 42 年的股息增长历史，当前交易价格不到 14 倍的收益。威瑞森的股息收益率为 6.2%，尽管近期面临挑战，但估值仍然适中，低于 11 倍的收益。艾伯维是一家股息之王，拥有超过 50 年的增长历史，股息收益率为 3.5%，但由于近期支出，其收益倍数较高。这些股票被推荐用于长期收入和增长潜力</p>

<p>Dividend growth stocks can be ideal long-term options for any investment portfolio. That's because they not only offer a good payout, but they may also rise over time, helping offset the negative effects of inflation. In a best-case scenario, your inflation-adjusted income ends up rising over time as a result.</p>
<div class="lb-trans"><p>股息增长股票可以是任何投资组合的理想长期选择。这是因为它们不仅提供良好的分红，而且随着时间的推移可能会升值，从而帮助抵消通货膨胀的负面影响。在最佳情况下，经过通货膨胀调整后的收入最终会随着时间的推移而增加。</p>
</div><p>There are many solid dividend stocks right now worth considering because they trade at modest valuations. Three stocks, in particular, have high yields, have grown their payouts, and look cheap. They are <strong>ExxonMobil</strong>(XOM 0.83%), <strong>Verizon Communications</strong>(VZ -0.59%), and <strong>AbbVie</strong>(ABBV 0.12%).</p>
<div class="lb-trans"><p>目前有许多值得考虑的优质股息股票，因为它们的估值适中。特别是有三只股票的收益率较高，分红增长，并且看起来便宜。它们是 <strong>埃克森美孚</strong>(XOM 0.83%)、<strong>威瑞森</strong>(VZ -0.59%) 和 <strong>艾伯维</strong>(ABBV 0.12%)。</p>
</div><p>Here's why you may want to consider buying these three cheap dividend growth stocks today.</p>
<div class="lb-trans"><p>以下是您可能想要考虑今天购买这三只便宜的股息增长股票的原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjAwODYvYS1jb3VwbGUtc2hha2luZy1oYW5kcy13aXRoLWFuLWFkdmlzb3IuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F820086%2Fa-couple-shaking-hands-with-an-advisor.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>1. ExxonMobil</h2>
<div class="lb-trans"><h2>1. 埃克森美孚</h2>
</div><p>Oil and gas giant ExxonMobil has increased its annual dividend for a remarkable 42 straight years. That's impressive when you consider the volatility inherent in the energy market and how that can weigh on an oil and gas producer's top and bottom lines.</p>
<div class="lb-trans"><p>石油和天然气巨头埃克森美孚已经连续 42 年增加其年度股息。这在考虑到能源市场固有的波动性以及这对石油和天然气生产商的收入和利润的影响时，实在令人印象深刻。</p>
</div><p>Currently, the stock yields 3.76%, which is better than the <strong>S&amp;P 500</strong> average yield of 1.3% and better than its three-year average of 3.4%. It's also a fairly cheap stock to buy, as ExxonMobil trades at less than 14 times its trailing earnings.</p>
<div class="lb-trans"><p>目前，该股票的收益率为 3.76%，高于 <strong>标准普尔 500</strong> 的平均收益率 1.3%，也高于其三年平均收益率 3.4%。这也是一只相对便宜的股票，因为埃克森美孚的市盈率不到 14 倍。</p>
</div><p>Over the years, the business has become bigger due to acquisitions, which have allowed it to become more efficient and profitable. Last year, it completed its acquisition of Pioneer Natural Resources, a move that more than doubled its production capacity in the Permian Basin.</p>
<div class="lb-trans"><p>多年来，由于收购，该业务规模不断扩大，这使其变得更加高效和盈利。去年，它完成了对先锋自然资源公司的收购，这一举措使其在二叠纪盆地的生产能力增加了一倍多。</p>
</div><p>For both its dividend income and long-term stability, ExxonMobil can make for a great stock to buy and hold.</p>
<div class="lb-trans"><p>无论是从股息收入还是长期稳定性来看，埃克森美孚都是一只值得购买和持有的优秀股票。</p>
</div><h2>2. Verizon Communications</h2>
<div class="lb-trans"><h2>2. 威瑞森</h2>
</div><p>The stock with the highest yield on this list is Verizon. It pays 6.2%, somewhat higher than the 5.8% it has averaged over the past five years. A big reason for that high yield is that the stock has struggled, falling more than 22% in the past five years. High interest rates, a lack of growth, and a capital-intensive business have all made the stock look fairly unappealing to investors.</p>
<div class="lb-trans"><p>该名单中收益率最高的股票是威瑞森。它的收益率为 6.2%，略高于过去五年的平均 5.8%。这一高收益率的一个主要原因是该股票表现不佳，在过去五年中下跌超过 22%。高利率、缺乏增长以及资本密集型业务使得该股票对投资者看起来相当不具吸引力。</p>
</div><p>But if your priority is a solid dividend, then this can be a great stock to buy, given its modest valuation. The telecom stock trades at less than 11 times its earnings. And while its growth prospects may not be fantastic, they aren't terrible, either. The company still anticipates between 2% and 2.8% growth in its core wireless service business this year. With estimated free cash flow of at least $17.5 billion, which is much more than the $11 billion it pays in dividends over the course of a full year, its payout still looks safe.</p>
<div class="lb-trans"><p>但如果您的优先考虑是稳定的股息，那么考虑到其适中的估值，这可以是一只很好的购买股票。该电信股票的市盈率不到 11 倍。尽管其增长前景可能并不理想，但也并非糟糕。公司仍预计今年核心无线服务业务的增长在 2% 到 2.8% 之间。预计自由现金流至少为 175 亿美元，远高于其每年支付的 110 亿美元股息，因此其分红仍然看起来安全。</p>
</div><p>Verizon has increased its dividend for 18 straight years, and for income investors, this can be an excellent stock to hang on to, as its modest valuation offers investors a good margin of safety.</p>
<div class="lb-trans"><p>威瑞森已经连续 18 年增加其股息，对于收入投资者来说，这可以是一只优秀的持有股票，因为其适中的估值为投资者提供了良好的安全边际。</p>
</div><h2>3. AbbVie</h2>
<div class="lb-trans"><h2>3. 艾伯维</h2>
</div><p>Rounding out this list is healthcare company AbbVie. Dating back to its time when it was part of <strong>Abbott Laboratories</strong>(it spun off in 2013), the stock is technically classified as a Dividend King, with its streak of annual increases going back 50-plus years. AbbVie can give investors the best of both worlds, as it's a growing pharma business, and it offers an attractive dividend, which currently yields 3.5%.</p>
<div class="lb-trans"><p>该名单的最后一项是医疗公司艾伯维。追溯到它作为 <strong>雅培</strong> 的一部分（2013 年分拆），该股票在技术上被归类为股息之王，其年度增长的连续记录超过 50 年。艾伯维可以为投资者提供两全其美的选择，因为它是一家不断增长的制药公司，并且提供吸引人的股息，目前的收益率为 3.5%。</p>
</div><p>The stock looks expensive, as it trades at an earnings multiple of around 80, but its numbers have been weighed down by acquisition-related expenses in its fourth-quarter results, which dragged its bottom line into the negative. And that's still weighing on its earnings multiple. But based on analyst expectations, the drugmaker's stock trades at just 15 times its estimated future profits.</p>
<div class="lb-trans"><p>该股票看起来较贵，市盈率约为 80 倍，但其数字受到收购相关费用的影响，在第四季度的业绩中拖累了其利润，导致其净利润为负。这仍然影响着其市盈率。但根据分析师的预期，该制药公司的股票仅以 15 倍的估计未来利润进行交易。</p>
</div><p>AbbVie is a top healthcare company with a vast portfolio of products in immunology, oncology, neuroscience, and even aesthetics (it owns Botox). For both growth and dividend investors, this can be a solid stock to buy right now.</p>
<div class="lb-trans"><p>艾伯维是一家顶尖的医疗公司，拥有广泛的产品组合，涵盖免疫学、肿瘤学、神经科学，甚至美容（它拥有 Botox）。对于增长和股息投资者来说，这可以是一只值得现在购买的优质股票。</p>
</div>

3 Cheap Dividend Growth Stocks to Buy Right Now

- 分红增长股票是长期投资组合的理想选择，能抵消通胀影响。  
- 当前推荐的三只股票为 ExxonMobil、Verizon 和 AbbVie，均具高收益和增长潜力。  
- ExxonMobil 连续 42 年增息，Verizon 股息高达 6.2%，AbbVie 具 50 年增息记录。  

3 只价格低廉的股息增长股票值得立即买入